Key Points
- Director Quiros sold 33,925 shares on March 23 at an average price of $60.39 for a total of $2,048,730.75, trimming his stake by 2.7% to 1,223,579 shares (about $73.9M).
- Recent results show mixed fundamentals: the stock opened at $58.16 (down ~2.4%), the company reported a quarter-beating EPS of ($0.09) vs. ($0.22) and revenue of $64.62M (up 45.2% YoY), but remains unprofitable with a negative net margin and ROE.
- Analyst sentiment is mostly positive—six Buys, one Hold and one Sell—with an average price target of $86.86 and several firms recently raising targets.
Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report) Director Quiros Juan Jose Chacon sold 33,925 shares of the business's stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $60.39, for a total transaction of $2,048,730.75. Following the completion of the transaction, the director owned 1,223,579 shares in the company, valued at approximately $73,891,935.81. The trade was a 2.70% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Establishment Labs Trading Down 2.4%
NASDAQ ESTA opened at $58.16 on Wednesday. The stock has a market capitalization of $1.71 billion, a P/E ratio of -33.43 and a beta of 0.91. The business has a 50 day simple moving average of $69.47 and a 200 day simple moving average of $61.79. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00. Establishment Labs Holdings Inc. has a one year low of $26.56 and a one year high of $83.31.
Establishment Labs (NASDAQ:ESTA - Get Free Report) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The firm had revenue of $64.62 million during the quarter, compared to the consensus estimate of $63.80 million. During the same period in the previous year, the firm posted ($1.19) earnings per share. The business's revenue was up 45.2% compared to the same quarter last year. Research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.
Institutional Investors Weigh In On Establishment Labs
Hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC boosted its holdings in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company's stock worth $1,105,000 after acquiring an additional 299 shares during the period. Patriot Financial Group Insurance Agency LLC raised its stake in shares of Establishment Labs by 5.8% during the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company's stock valued at $261,000 after purchasing an additional 350 shares during the period. Handelsbanken Fonder AB lifted its holdings in Establishment Labs by 7.3% during the 4th quarter. Handelsbanken Fonder AB now owns 8,800 shares of the company's stock worth $641,000 after purchasing an additional 600 shares in the last quarter. Swiss National Bank lifted its holdings in Establishment Labs by 1.8% during the 4th quarter. Swiss National Bank now owns 34,200 shares of the company's stock worth $2,492,000 after purchasing an additional 600 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Establishment Labs in the 4th quarter worth about $47,000. Institutional investors own 72.91% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on ESTA. Stephens lifted their price objective on shares of Establishment Labs from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. Needham & Company LLC upped their target price on shares of Establishment Labs from $84.00 to $86.00 and gave the stock a "buy" rating in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Establishment Labs in a research report on Monday, December 29th. BTIG Research lifted their price target on Establishment Labs from $86.00 to $88.00 and gave the company a "buy" rating in a research note on Tuesday, February 24th. Finally, Citigroup decreased their price objective on Establishment Labs from $81.00 to $74.00 and set a "neutral" rating for the company in a report on Wednesday, March 11th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Establishment Labs has an average rating of "Moderate Buy" and an average target price of $86.86.
View Our Latest Stock Analysis on ESTA
Establishment Labs Company Profile
(
Get Free Report)
Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.
The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
